In mid-August the FDA approved the novel compound pretomanid for the treatment of XDR-TB and the treatment of MDR-TB for patients intolerant of, or not responding to, standard MDR-TB treatment.
We are often asked about the safety of sunscreens. The American Academy of Dermatology have put together a very helpful set of ‘frequently asked questions’.
A fascinating new systematic review of meta-analyses and trials assessing the efficacy of nutritional supplements has shown some interesting results.
A medicine safety letter highlights the risk of acute kidney injury in patients treated with fluoroquinolones concomitantly with ace-inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).